Plain-English translation of NCT07264998 on ClinicalTrials.gov ↗ ·
This is an observational study that looks at the natural bacteria living in your gut (called the microbiome) to understand why some patients taking Abemaciclib for hormone receptor-positive breast cancer develop severe diarrhea while others don't. Researchers will compare gut bacteria samples from patients who experience diarrhea with those who don't, hoping to uncover patterns that might explain this common side effect.
Abemaciclib is an effective cancer treatment, but many patients develop diarrhea that can be severe enough to disrupt treatment and daily life. Right now, doctors don't fully understand why this happens to some patients and not others, so this study aims to discover whether differences in gut bacteria might be the explanation.
You likely qualify if…
You likely don't qualify if…
You'll continue taking your Abemaciclib exactly as prescribed by your oncologist—no changes to your treatment. During the study, you'll be asked to provide stool samples at specific times and may be asked to give an optional blood sample. Researchers will analyze these samples in the lab to study your gut bacteria and look for patterns between patients who develop diarrhea and those who don't.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China